Yale School of Medicine - Internal Medicine

In this review of March 2025 in dermatology news, we highlight a variety of notable stories covered in the field regarding pipeline news and recent data.

Latanya Benjamin, MD, and Lindsay Ackerman, MD, joins The Medical Sisterhood in a live recording at AAD 2025 to discuss advocacy, mentorship, and empowerment.

In this interview with Christopher Bunick, MD, PhD, at AAD 2025, he discusses his update given in a presentation regarding acne and rosacea treatments.

This interview features a discussion with Christopher Bunick, MD, PhD, regarding recent controversies in acne and rosacea related to benzene and benzoyl peroxide.

Researchers from Yale looked at where money that flows through the healthcare system, and to for-profit companies goes.

In this episode, James Q. Del Rosso, DO, joins The Medical Sisterhood for a conversation about empowerment and the benefits of female role models.

A new tool may enable earlier identification of heart failure, potentially reducing hospitalizations and premature death.

New research tested how specialized hypertennsion medical curriculum impacted residents’ treatment of hypertensive urgency in the outpatient setting.

In a Q&A, Kasia Lipska, MD, MHS, discusses the impact of type 2 diabetes on the immune system and findings from her recent research.

Most deprescribing interventions consist of a clinician being alerted to a potential problem with the patient’s medication but does not provide guidance to the clinician about how to communicate with the patient.

In a Q&A, Kang discusses the role of MAVS in host resilience, aging as a contributing factor of lung disease, and the link between viral innate immunity and aging biology.

A survey suggests ablation leads to improved sports performance in athletes with atrial fibrillation.

A new app being developed, JomCare, will ask study participants twice a day about their substance cravings and their intention to engage in drug use.

Shadi Kourosh, MD, MPH, joins The Medical Sisterhood to discuss advocacy, mentorship, and the empowerment of women in medicine.

Susan Taylor, MD, and Linda Stein Gold, MD, join The Medical Sisterhood for an intimate conversation on the importance of role models and mentors.

Computer-aided detection during colonoscopies with AI may help increase adenoma detection rates.

The Pressure Check study at Yale aims to address disparities in blood pressure management.

This interview with Bunick highlighted the LEVEL UP phase 3b/4 trial findings regarding upadacitinib treatment of patients with atopic dermatitis.

Alexandra Golant, MD, joins the program for a deep dive into her experience with motherhood, striking an optimal balance between her career and her personal life, and more!

Looking to the future of atopic dermatitis treatment, the panel discusses ongoing research and promising emerging therapies.

In this episode, Tina Bhutani, MD, MAS, joins The Medical Sisterhood for a discussion about confronting imposter syndrome as a woman in medicine.

Focusing on clinical scenarios, experts on atopic dermatitis discuss how their treatment approaches vary depending on patient-specific factors.

Dermatologists outline the role of targeted therapies and JAK inhibitors in the treatment of patients with atopic dermatitis.

Following a review of findings from the LEVEL UP study, an expert on atopic dermatitis shares what we’ve learned from long-term data on upadacitinib and JAKi.

Jonathan Silverberg, MD, PhD, MPH, reviews findings from the LEVEL UP study investigating upadacitinib in patients with moderate-to-severe atopic dermatitis.

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.

Experts on atopic dermatitis compare the safety profile of JAK inhibitors with traditional and more advanced treatments currently available for patients.

The Medical Sisterhood, hosted by Mona Shahriari, MD, is the latest multimedia program from HCPLive Dermatology!

A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms.